TEVA Stock Forecast 2023, 2024, 2025, 2030 | Cavix
Please disable Ad Blocker before you can visit the website !!!
thumbnail

TEVA Stock Forecast 2023, 2024, 2025, 2030

by Cavix   ·  December 10, 2022   ·  

TEVA Stock Forecast 2023, 2024, 2025, 2030

by Cavix   ·  December 10, 2022   ·  

Generic medications, specialty medications, and biologic products are developed, produced, marketed, and distributed by Teva Pharmaceutical Industries Limited in North America, Europe, and other countries. The business sells cytotoxic substances, hormones, high-potency medications, and sterile goods in a range of dosage forms, include tablets, capsules, fluids, transdermal patches, ointments, & creams. Additionally, it creates, produces, and markets active medicinal components. It also emphasizes the respiratory, oncology, pain, and central nervous system systems.

Copaxone for the therapy of relapsing forms of parkinson’s disease, AJOVY for the prevention of migraines, and AUSTEDO for the therapy of autonomic dysfunction and chorea linked to Huntington disease are some of its medicines for the central nervous system. ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, & AirDuo RespiClick/ArmonAir RespiClick are among the company’s respiratory medications used for the treatment of asthma and chronic obstructive disease.

Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim are some of its oncology-related medications. A midodrine suspension for the treatment of people with schizophrenia is being developed and commercialized by Teva Pharmaceutical Industries Limited in partnership with MedinCell. Israel’s Tel Aviv-Yafo serves as the company’s headquarters. It was established in 1901.

Who Owns Teva Pharmaceutical Industries?

48.85% retail investors, 0.75% Teva Pharmaceutical Industries officials, & 50.39% institutional shareholders own Teva Pharmaceutical Industries (NYSE: TEVA). The largest individual shareholder of Teva Pharmaceutical Industries is Capital Research Global Investors, which holds 117.19 million shares, or 10.55% of the firm. TEVA stock owned by Capital Research Global Investments are presently valued at $989.09M.

Institutional investors hold 46.22% of the TEVA stock. In the last 24 months, institutional investors acquired a total of 161,220,422 shares. This volume of purchases entails roughly $1.49B in transactions. In the past 24 months, institutional investors has purchased a total of 211,930,292 shares. The $2.19B in transactions represented by this share sale volume.

The following investors as well as hedge funds have purchased the most shares of TEVA stock out of the 333 investment firms who bought shares over the past 24 months:

Capital Research Global Investors ($13.47 million), Exor Capital LLP ($11.52 million), Phoenix Holdings Ltd. ($10.30 million), Menora Mivtachim Holdings LTD. ($6.53 million), Harel Insurance Investments & Financial Services Ltd. ($6.16 million), Bank of Montreal Can ($5.74 million), and BlackRock Inc. ($5.32 million) are among the top investors.

TEVA Competitors

Jazz Pharmaceuticals (JAZZ), Legend Biotech (LEGN), Dr. Reddy’s Laboratories (RDY), Catalent (CTLT), Sarepta Therapeutics (SRPT), Karuna Therapeutics (KRTX), Ascendis Pharma A/S (ASND), Organon & Co. (OGN), United Therapeutics (UTHR), as well as Elanco Animal Health are some of Teva Pharmaceutical Industries’ top rivals (ELAN).

Analysts favor other medical firms more than Teva Pharmaceutical Industries. The average consensus rating for medical businesses is Buy, while the recommendation for Teva Pharmaceutical Industries is Hold.

Teva Pharmaceutical Industries is preferred by customers over other medical businesses. Teva Pharmaceutical Industries received an outperform vote from 67.64% of users compared to an average of 66.26% for medical firms.

Jazz Pharmaceuticals And Teva Pharmaceutical Industries

Teva Pharmaceutical Industries’ profit income is -8.52%, while Jazz Pharmaceuticals’ net margin is -0.52%. Teva Pharmaceutical Industries’ return on equity was surpassed by Jazz Pharmaceuticals’ equity return of 30.71%. With a beta of 0.76, Jazz Pharmaceuticals’ share price is 24% less volatile than that of the S&P 500.

Comparatively, TEVA stock price is 25% more variable than the S&P 500, according to its beta of 1.25. 13 more media stories about Jazz Pharmaceuticals than Teva Pharmaceutical Industries were published in the past week. Jazz Pharmaceuticals received 18 mentions from MarketBeat while Teva Pharmaceutical Industries received 5 mentions.

Teva Pharmaceutical Industries outperforms Jazz Pharmaceuticals in terms of revenue and earnings. Teva Pharmaceutical Industries and Jazz Pharmaceuticals are currently trading at higher price-to-earnings ratios, indicating that Teva Pharmaceutical Industries is currently the more expensive company.

When compared by MarketBeat users, Teva Pharmaceutical Industries scored 244 more votes for outperformance than Jazz Pharmaceuticals. But only 67.64% of people awarded Teva Pharmaceutical Industries an indelible stamp, while 80.31 percent of users chose Jazz Pharmaceuticals.

How Much Money Did TEVA Make The Last Quarter?

Teva Pharmaceutical Industries (NYSE: TEVA) reported Q3 2022 profit per share (EPS) of $0.05 on November 3, 2022, an increase of 80.77% over the previous year. $56.00 million was the total revenue for Teva Pharmaceutical Industries during the quarter.

TEVA stock earnings (EPS) for the same quarter last year were $0.26. The profits of Teva Pharmaceutical Industries increased year over year as of Q4 2022. The annual revenue for Teva Pharmaceutical Industries was -$1.29 billion. In the last 12 months, TEVA has not distributed any dividends.

Teva Pharmaceutical Industries (NYSE: TEVA) announced Q3 2022 sales of $3.60 billion on November 3, 2022, an increase of 7.51% from the previous year. Teva Pharmaceutical Industries’s sales for the same quarter previous year was $3.89 billion. The revenue of Teva Pharmaceutical Industries increased by -6.72% annually as of Q4 2022.

Fundamentals Of The Teva Pharmaceutical Industries

The valuation score for TEVA is 14, which is higher than the industry average for Drug Manufacturers  Specialty & Generic. Right now, TEVA is only passing one of seven requirements for due diligence. The Financials score for TEVA is 11, which is higher than the industry average for Drug Manufacturers  Specialty & Generic. Right now, TEVA is only passing one of seven requirements for due diligence.

The forecast score for TEVA is 10, which is higher than the sector average for Drug Manufacturers – Specialty & Generic. TEVA is only passing one of nine checks for due diligence. The performance score for TEVA is 0, which is the same as the average score for the Drug Manufacturers – Specialty & Generic industry.

TEVA is currently failing zero out of ten checks for due diligence. The Dividend score for TEVA is 0, which is the same as the industry average for Drug Manufacturers – Specialty & Generic. TEVA is currently failing zero of five criteria for due diligence.

How Much Is Teva Pharmaceutical Industries Stock Currently Worth?

1,110,644,809 shares of Teva Pharmaceutical Industries are now on the market. With shares of TEVA stock stuff trading at $8.44 each, the company’s market capitalization is $9.37B.

The initial TEVA stock was $5.91 on December 31, 1997. Your return over the past 24 years would have reached 42.71%, or an annualized return of 1.49%, if you had purchased Teva Pharmaceutical Industries shares at $5.91.

As of December 10, 2022, Teva Pharmaceutical Industries had a $9.37B market cap. The entire market value of a publicly listed company’s outstanding shares is known as market cap (market capitalization).

The market capitalization of Teva Pharmaceutical Industries is determined by dividing the $8.44 TEVA stock price of the company today by the 1,110,644,809 shares that are now outstanding.

What Is The Teva Pharmaceutical Industries Price Target?

The average price goal for TEVA, as reported by 8 Wall Street experts that have provided a 1-year TEVA price target, is $10.38; the the highest and lowest TEVA share value forecasts, respectively, are $13.00 and $7.00.

By November 23, 2023, on average, Wall Street traders expect TEVA stock price to reach $10.38. The typical analyst’s prognosis for the price of Teva Pharmaceutical Industries’ stock predicts a potential increase of 22.93% from the firm’s present $8.44 per share.

Financial Summary For TEVA

Failed financial due diligence checks: TEVA’s -$1.13B earnings are insufficient to pay interest on its debt. On the TEVA balance sheet, long-term liabilities outnumber short-term assets. TEVA can securely service its $21.62 billion in debt thanks to its cash flow from operations of $1.07 billion.

On the TEVA income statement, short-term liabilities outnumber short-term assets. With a 3.96 ratio, TEVA’s debt to equity is quite high. In the last year, TEVA’s profit margin has decreased from 4.5% to -8.5%.

Newest TEVA Analyst Predictions

On November 23, 2022, Piper Sandler’s top 14% analyst David Amsellem lowers his firm’s price objective for TEVA from $8.00 to $7.00 while maintaining a strong sell recommendation. On November 14, 2022, Chris Schott, a JP Morgan analyst who ranks in the bottom 23%, downgrades TEVA to an extreme sell recommendation and decreases their price objective from $11.00 to $10.00.

On November 7, 2022, Gary Nachman, the bottom 12% BMO Capital analyst, lowers his firm’s price target for TEVA from $11.00 to $10.00 while maintaining a hold rating. On October 21, 2022, Glen Santangelo, the top 42% expert from Jefferies, assigns TEVA a strong buy rating as well as releases their $10.00 price objective.

On August 5, 2022, Jason Gerberry, a high 20% expert from Bank of America, lifts their price objective for TEVA from $10.00 to $13.00 and upgrades the TEVA stock to a strong buy rating.

Teva Pharmaceutical Industries Stock Forecast 2022

The revenue for Teva Pharmaceutical Industries in 2022 is -$1,290,000,000. The average TEVA earnings estimate from 6 Wall Street experts for 2022 is $2,721,079,782, with the current estimate coming in at $2,665,547,542 and the highest estimate coming in at $2,787,718,471.

In 2022, Teva Pharmaceutical Industries will earn $15,142,000,000 in revenue. TEVA’s revenue is expected to be $17,041,600,671,919 on average by 5 Wall Street analysts in 2022, with the lowest estimate being $16,894,906,705,546 and the highest estimate being $17,203,777,026,929.

Analysts expect TEVA’s earnings per share (EPS) to be $2.45 on average for 2022, with the minimum EPS projection coming in at $2.40 and the highest EPS TEVA stock forecast coming in at $2.51.

Teva Pharmaceutical Industries Stock Forecast 2023

Teva Pharmaceutical Industries Stock Forecast 2023

The average TEVA stock forecast from 6 Wall Street experts for 2023 is $2,709,973,334, with the current estimate coming in at $2,687,760,438 and the highest estimate coming in at $2,743,292,678.

The average estimate of TEVA’s revenue for 2023 from five Wall Street analysts is $17,186,193,298,313, with the current estimate coming in at $16,568,488,196,181 and the highest estimate coming in at $17,448,229,949,390.

Analysts expect TEVA stock forecast (EPS) to be $2.44 on average for 2023, with the minimum EPS projection coming in at $2.42 and the maximum TEVA stock forecast coming in at $2.47.

Teva Pharmaceutical Industries Stock Forecast 2024

TEVA stock forecast is expected to earn $2,843,250,711 in 2024, with the minimum earnings estimate coming in at $2,787,718,471 and the maximum profit estimate coming in at $2,920,995,848.

The TEVA stock forecast in 2024 is $17,409,899,375,742, with the lowest revenue estimate coming in at $16,589,368,318,590 and the largest income estimate coming in at $17,860,279,173,529. The expected EPS for TEVA in 2024 is $2.56.

(NYSE: TEVA) TEVA stock forecast ROA is 6.88%, which is less than the anticipated 13.44% average for US Drug Manufacturers – Specialty & Generic. (NYSE: TEVA) is expected to have a great ROE of 34.71%.

Teva Pharmaceutical Industries Stock Forecast 2025

Teva Pharmaceutical Industries Stock Forecast 2025

Twelve forecasts are made for the TEVA stock forecast for the year 2025, with an average prediction of 1993.51, a high prediction of 2043.13, and a low prediction of 1962.6.

From the most recent price of 3309.0, the average TEVA stock forecast for 2025 shows a -39.75% decline.

Teva Pharmaceutical Industries Stock Forecast 2027

Twelve predictions are made for each month of 2027 for the TEVA stock forecast for 2027 (5 years), with an average prediction of 1977.32, a high prediction of 2214.56, and a low prediction of 1885.73.

The typical Teva Pharmaceutical Industries Limited stock estimate for 2027 shows a decline from the most recent price of 3309.0 of -40.24%.

Teva Pharmaceutical Industries Stock Forecast 2030

teva stock

Twelve forecasts are made for each month of 2030 regarding the price of TEVA stock forecast, with an average price prediction of 5404.93, a high prediction of 5924.71, and a low prediction of 4902.53.

The typical TEVA stock forecast for 2030 anticipates an increase from the most recent price of 3309.0 of 63.34%.

Teva Pharmaceutical Industries Stock Forecast 2032

Four forecasts are made for each month of 2032 for the TEVA stock forecast for 2032 (10 years), with an average prediction of 7162.58, a high prediction of 7201.45, and a low prediction of 7127.99.

The typical TEVA stock forecast for 2032 shows a growth of 116.46% from the most recent price of 3309.0. View more projections below, please.

Leave a Reply